Cocrystal Pharma, Inc. (NASDAQ:COCP) Short Interest Down 67.1% in May

Cocrystal Pharma, Inc. (NASDAQ:COCP) was the target of a significant decrease in short interest during the month of May. As of May 15th, there was short interest totaling 192,682 shares, a decrease of 67.1% from the April 30th total of 586,422 shares. Based on an average daily volume of 138,014 shares, the short-interest ratio is presently 1.4 days. Approximately 1.9% of the company’s shares are sold short.

Institutional Investors Weigh In On Cocrystal Pharma

A hedge fund recently bought a new stake in Cocrystal Pharma stock. DRW Securities LLC bought a new position in Cocrystal Pharma, Inc. (NASDAQ:COCP) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned 0.24% of Cocrystal Pharma as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 6.72% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut shares of Cocrystal Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 22nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $6.00.

Cocrystal Pharma Price Performance

Shares of COCP traded down $0.01 during trading hours on Friday, hitting $1.12. The stock had a trading volume of 101,603 shares, compared to its average volume of 130,481. Cocrystal Pharma has a 52 week low of $0.86 and a 52 week high of $2.67. The stock has a market capitalization of $15.44 million, a price-to-earnings ratio of -1.53 and a beta of 1.50. The company’s fifty day moving average is $1.29 and its two-hundred day moving average is $1.11.

Cocrystal Pharma (NASDAQ:COCP) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). The company had revenue of $0.23 million during the quarter, compared to analysts’ expectations of $0.23 million. Equities analysts predict that Cocrystal Pharma will post -0.67 EPS for the current fiscal year.

About Cocrystal Pharma

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.